Therefore, vaccine-elicited CD8+ T cells should ideally be of high T cell avidity or antigen-triggering sensitivity to recognize immunogenic peptide-major histocompatibility complex class I (pMHC I) complexes and effectively eliminate cancer cells [16,17]. Here, CD8A is linked to cancer.